<DOC>
	<DOC>NCT02226315</DOC>
	<brief_summary>This study will evaluate the clinical performance of massively parallel sequencing (MPS) using the MaterniT21 PLUS LDT in the detection of fetal aneuploidy in circulating cfDNA extracted from a maternal blood sample obtained from women pregnant with a multiple gestation who were at increased risk for fetal aneuploidy.</brief_summary>
	<brief_title>Clinical Performance of the MaterniT21 PLUS LDT in Multiple Gestation Pregnancies</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<criteria>Subject was pregnant with a multiple gestation and received NIPT with the MaterniT21 PLUS LDT and a valid test result is available; Subject was 18 years of age or older at the time of NIPT; Subject provides signed and dated informed consent in English; Subjects' treating physician is not located in the United States.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>noninvasive prenatal testing</keyword>
</DOC>